MV

History

History

History of KANEKA MEDIX

Our company was established in September 1993 as a wholly owned subsidiary of Kaneka Corporation.
Since then, we have been providing products and services that meet the specific needs of healthcare settings as a Japanese medical device manufacturer.

Kaneka entered the medical device business through blood purification.

1986

Started sales of an adsorption type plasma purification device.
Entered into the nephrology (dialysis) field.

Established Kaneka Germany (now Kaneka Pharma Europe) in Frankfurt.

1987

Established KANEKA MEDIX CORPORATION.

1993

Inherited the iconic medical tubing brand SILASCON® from Dow Corning and started sales.

1994

Started sales of a lacrimal duct tube.
Entered the ophthalmology field.

Completed the construction of the KANEKA MEDIX CORPORATION KANAGAWA PLANT.

1996

Started sales of a PTCA balloon catheter.
Entered the cardiovascular field.

Established Kaneka Pharma America (now Kaneka Medical America LLC) in New York, USA.

1997

Obtained FDA approval for an adsorption type plasma purification system.

Relocated Tokyo office to Tennozu.

1999
2000

Started sales of an adsorption type blood purification device.

Launched the TRANVAS brand.

Integrated the sales of Kaneka's intervention business into KANEKA MEDIX CORPORATION.

2001

Established Biomaster.

2002

Started sales of an aneurysm embolization coil.
Entered the neurosurgery field.

Started sales of a PTA balloon catheter.
Entered the vascular access intervention therapy field.

Started sales of a thrombus aspiration catheter.

Started sales of a penetration catheter.

Established KANEKA MEDIX CORPORATION Osaka Logistics Center within Kaneka Osaka Manufacturing Site.

2003

Integrated the sales of Kaneka's blood purification business into KANEKA MEDIX CORPORATION.

2005

Started sales of a blood flow measuring system.

Started sales of a PTA balloon catheter.
Entered the peripheral field.

Opened Cellport Clinic Yokohama.

2006

Established Kaneka Pharma Vietnam (now Kaneka Medical Vietnam).

2007

Established a customer service center in Tennozu.

2008

Opened the Tokyo Logistics Center.

2009

Relocated the Sapporo Sales Office and the Nagoya Sales Office.

2010

Started the overseas expansion of the PTCA balloon catheter.
(Areas: EMEA, ASEAN regions, Australia, New Zealand, India)

Acquired a shareholding of River Seiko and established River Seiko.

Opened the Sendai Sales Office.

2013

Started the overseas expansion of blood purification products (adsorption type blood purification devices).
(Areas: EMEA, North America and Central and South America)

2014

Started the overseas expansion of the PTA balloon catheter (for peripheral vessels) (Area: China)

Started the overseas expansion of the lacrimal duct tube.

Started the overseas expansion of the aneurysm embolization coil.
(Areas: EMEA, Vietnam and Central and South America)

Opened the Hiroshima Sales Office.

2015

Obtained FDA approval for the adsorption type blood purification device.

Started sales of a biliary dilatation balloon catheter.
Entered the gastroenterology field.

Opened the Settsu office.

2016

Relocated the Tokyo office and the Customer Service Center to Akasaka.

2017
2019

Started sales of an electrode catheter.
Entered the arrhythmia field.

Changed the company name from River Seiko to KANEKA MEDICAL TECH.

2020

Started sales of a biliary metallic stent.

Started sales of a pleural fluid/ascites concentration filter and a pleural fluid/ascites filtration filter.

Completed the construction of the new medical device plant of Kaneka Medical Vietnam.

2022

Kaneka fully acquired Japan Medical Device Technology.

2023

Kaneka completed the construction of Tomatoh Manufacturing Site.

Kaneka signed an exclusive distribution agreement in Japan with Israeli Company for a cerebral thrombus retriever.

2024

Started sales of a papillotomy knife.

Started sales of a cutting type PTCA balloon.

Started sales of an intracardiac defibrillation electrode catheter.

Started sales of a cerebral infarction treatment device.